Lakewood-Amedex Biotherapeutics, Inc.
Research Lakewood-Amedex Biotherapeutics, Inc. (LABT) on Bullrun: market cap USD 845.99K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLABT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 845.99K
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.77M
- Free cash flow-USD 2.10M
Valuation Snapshot
latest market cap is USD 845.99K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 3.85M | -USD 1.94M | n/a | -2.76 | USD 236.40K | USD 1.66M | -USD 1.96M |
| FY2024 | USD 0 | -USD 4.86M | -USD 5.73M | n/a | -6.94 | USD 681.10K | USD 272.86K | USD 409.61K |
| FY2023 | USD 0 | -USD 8.28M | -USD 6.82M | n/a | -11.84 | USD 2.53M | USD 578.88K | USD 4.56M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 845.99K | n/a | n/a | n/a |
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lakewood-Amedex Biotherapeutics, Inc.'s market cap?
Lakewood-Amedex Biotherapeutics, Inc.'s market capitalization is USD 845.99K.
What does Lakewood-Amedex Biotherapeutics, Inc. do?
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025.